Array BioPharma, Inc.

AstraZeneca and Merck & Co. appear poised to tap a larger market opportunity with the MEK inhibitor Koselugo (selumetinib) after the drug showed a benefit in adults with the rare condition neurofi

The pace of new biopharmaceutical financings has slowed as summer enters the last sleepy weeks of August, but the handful of recent significant funding announcements have been quite large, including

A player in the oncology field since 1978, Pierre Fabre has been busy this month advancing its cancer ambitions through a pact with Vernalis (R&D) Ltd. and the acquisition of Vertical Bio . The F

Pfizer Inc. has been on an M&A buying spree over the last year, powered by the unprecedented returns from its COVID-19 vaccine Comirnaty and antiviral Paxlovid and with the aim of finding the next bi